Pathoimmunobiology of Atopic Dermatitis (AD)

Interactive Dialogue Session

Emma Guttman-Yassky, MD, PhD

Emma Guttman-Yassky, MD, PhD

Professor and Vice Chair, Dermatology
Mark Lebwhol, MD

Mark Lebwhol, MD

Sol and Clara Kest Professor and Chairman
Lisa Beck, MD

Lisa Beck, MD

Professor, Department of Dermatology and Medicine (Allergy/Immunology and Rheumatology)

Program Medium

Internet-based program


Estimated Time to Complete Educational Activity

1.5 hours


Course Overview

In this web-based program, physicians will learn how recent advances in basic and clinical research have helped to advance the management of atopic dermatitis.

Release Date: January 6, 2017

Expiration Date: January 6, 2019


Method of Physician Participation Utilized in Learning Process

There are no fees for participating and receiving CME credit for this activity. During the period July, 23, 2016  through July 23, 2018 participants must:
1) read the learning objectives and faculty disclosures;
2) study the educational activity, and are expected to view all 9 segments totaling 1.5 hours to successfully complete the activity and earn CME credit;
3) register and complete the evaluation form and post-test;
4) score 100% on the post-test; and
5) print out your CME certificate.



Participation in this WebCAST is complimentary, and clinicians are invited to view this CME-certified program and/or share this invitation with other colleagues, departmental staff members, and healthcare professionals.


Grantor Support

Supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.


Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Massachusetts Medical School and CMEducation Resources, LLC. ‘The University of Massachusetts Medical School is accredited by the ACCME to provide continuing medical education for physician.


Credit Designation Statement

The University of Massachusetts Medical School designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


Policy on Faculty & Provider Disclosure

Advancing Knowledge in Healthcare requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to AKH policy. The existence or absence of COI for everyone in a position to control content will be disclosed to participants prior to the start of each activity.


Other Credits

American Nurses Credentialing Center (ANCC) accepts AMA PRA Category 1 Credits™ from organizations accredited by the ACCME.
American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credits™ from organizations accredited by the ACCME.
American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credits™ from organizations accredited by the ACCM.


Program Faculty and Disclosure

Lisa A. Beck, MD 
Professor, Department of Dermatology 
Professor, Department of Medicine, Allergy/ Immunology and Rheumatology 
University of Rochester Medical Center School of Medicine and Dentistry 
Rochester, NY 

Dr Beck has disclosed the following financial relationships: Consultant: AbbVie Inc., Array Biopharma, Celgene Corporation, Genentech, Inc., Ironwood, Janssen Pharmaceuticals, Inc, LEO Pharmaceuticals, Lilly, MedImmune, Novartis, Regeneron Pharmaceuticals, Inc., Unilever and Ziarco 
Contracted Research: AbbVie Inc., Genentech, Inc., Regeneron Pharmaceuticals, Inc. Stock: Medtronic, Inc., Pfizer Inc. 

Mark Lebwohl, MD
Professor and Chairman 
Department of Dermatology 
The Mount Sinai School of Medicine 
New York, NY 

Dr Lebwohl discloses no financial relationships with pharmaceutical or medical product manufacturers.

Emma GuttmanYassky, MD, PhD – Program Chair 
Professor and Vice Chair, Dermatology 
Director, Center for Excellence in Eczema and Laboratory for Inflammatory Skin Diseases 
Icahn School of Medicine at Mount Sinai Medical Center 
New York, New York 

Consultant: AbbVie Inc., Almirall, Anaco, Asana Biosciences, Celgene Corporation, Dermira Inc., Eli Lilly, Galderma, Glenmark Pharmaceuticals, Kiowa Kirin, LEO Pharmaceuticals, Medimmune, Mitsubishi Tanabe, Novartis, Pfizer Inc., Regeneron, Sanofi-aventis, Stiefel/GlaxoSmithKline, Vitae Contracted Research: Celgene Corporation, Eli Lilly, Glenma, Janssen Biotech, LEO Pharmaceuticals, Medimmune, Novartis, Vitae


Educational Objectives

Upon completion of this activity, participants will be able to: 

  • Manage patients with moderate-to-severe atopic dermatitis, and understand the lifelong disease burden of AD and associated disorders; 
  • Apply national and international professional association-based guidelines for assessment and diagnosis of atopic dermatitis to the front line of patient care; 
  • Detail the epidemiology, disease burden, and quality-of-life dimensions associated with atopic dermatitis based on severity of disease and health care disparities; 
  • Sequence and combine non-pharmacologic and pharmacologic therapies based on severity of disease, biomarkers, and guidelinedirected roadmaps for optimizing management of atopic dermatitis; 
  • Evaluate, monitor, and intervene in patients with moderate-to-severe atopic dermatitis who have treatment failures; 
  • List the scientific advances and improvements in our understanding the pathoimmunobiology of atopic dermatitis, with a focus on novel treatment targets, cytokine signaling systems, Th2 immune response, and the role of interleukin-mediated inflammation in AP; 
  • Explain the rationale for evaluating biologic agents and targeting new mechanisms-of-action and molecular signatures in patients with moderate-to-severe and/or resistant atopic dermatitis; 
  • Apply the results of landmark clinical trials in atopic dermatitis, including those evaluating the safety and efficacy of interleukintargeted therapies, in patients with moderate-tosevere atopic dermatitis.


Hardware and Software Requirements:

To participate in this program, viewers must have a PC or Macintosh computer that has active, ongoing internet access for the duration of the program, as well as a compatible Flash-viewer. An email address is required for registration, and a printer is required to print out the CME certificate.


Privacy Policy

When you participate in a CME activity offered by CMEducation Resources, we ask you for your name, degree, affiliation, street address, telephone number, fax number, and/or e-mail address (the "Information"). We use that Information in the following ways:

• We use the Information to grade your post-test and to send you a certificate of completion of the CME activity. If we use a third-party company to grade your post-test and issue certificates of completion, we will give the Information to that company for that purpose only.

• For each CME activity that you take, you must complete an evaluation questionnaire. That questionnaire asks if you are willing to participate in a follow-up survey. If you answer yes, we will use your name and contact information to send you the survey.

• We may use the Information to send you information about other CME activities that CMEducation Resources is offering.

• If our company is acquired by or merged into another company, we may make the Information available to the new owner/entity to use in the ways described above, to enable it to continue our business.

• You should check this privacy policy periodically to see whether we have made any changes